Zi-Wei Ye

Zi-Wei Ye

Auto-generated profile, based on publicly available information

Zi-Wei Ye

The University of Hong Kong

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2022 in Science
Verified
Journal Article
Closed access
Shuofeng YuanShuofeng Yuan
Shuofeng Yuan
ZYZi-Wei Ye
Zi-Wei Ye
RLRonghui Liang
Ronghui Liang
KTKaiming Tang
Kaiming Tang
AZAnna Jinxia Zhang
Anna Jinxia Zhang
Jasper Fuk Woo ChanJasper Fuk Woo Chan
Jasper Fuk Woo Chan
The in vivo pathogenicity, transmissibility, and fitness of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron (B.1.1.529) variant are not well understood. We compared these virological attributes of this new variant of concern (VOC) with those of the Delta (B.1.617.2) variant in a Syrian hamster model of COVID-19. Omicron-infected hamsters lost significantly less body weight and exhibited reduced clinical scores, respiratory tract viral burdens, cytokine and chemokine dysregulation, and lung damage than Delta-infected hamsters. Both variants were highly transmissible through contact transmission. In noncontact transmission studies Omicron demonstrated similar or higher transmissibility than Delta. Delta outcompeted Omicron without selection pressure, but this scenario changed once immune selection pressure with neutralizing antibodies—active against Delta but poorly active against Omicron—was introduced. Next-generation vaccines and antivirals effective against this new VOC are therefore urgently needed.

28 August 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
Shuofeng YuanShuofeng Yuan
Shuofeng Yuan
HIN CHUHIN CHU
HIN CHU
JHJingjing Huang
Jingjing Huang
Xiaoyu ZHAOXiaoyu ZHAO
Xiaoyu ZHAO
ZYZi-Wei Ye
Zi-Wei Ye
KYKwok-Yung Yuen
Kwok-Yung Yuen
Host AP2M1 protein is exploited by diverse pathogenic viruses via their YxxØ protein motif during viral replication cycle.

1 January 2021 in Emerging Microbes & Infections
Verified
Journal Article
Open access
ZYZi-Wei Ye
Zi-Wei Ye
Shuofeng YuanShuofeng Yuan
Shuofeng Yuan
Jasper Fuk Woo ChanJasper Fuk Woo Chan
Jasper Fuk Woo Chan
Anna Jinxia ZhangAnna Jinxia Zhang
Anna Jinxia Zhang
CYChing-Yun Yu
Ching-Yun Yu
Dong-Yan JinDong-Yan Jin
Dong-Yan Jin
Effective treatments for coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are urgently needed. Dexamethasone has been shown to confer survival benefits to certain groups of hospitalized patients, but whether glucocorticoids such as dexamethasone and methylprednisolone should be used together with antivirals to prevent a boost of SARS-CoV-2 replication remains to be determined. Here, we show the beneficial effect of methylprednisolone alone and in combination with remdesivir in the hamster model of SARS-CoV-2 infection. Treatment with methylprednisolone boosted RNA replication of SARS-CoV-2 but suppressed viral induction of proinflammatory cytokines in human monocyte-derived macrophages. Although methylprednisolone monotherapy alleviated body weight loss as well as nasal and pulmonary inflammation, viral loads increased and antibody response against the receptor-binding domain of spike protein attenuated. In contrast, a combination of methylprednisolone with remdesivir not only prevented body weight loss and inflammation, but also dampened viral protein expression and viral loads. In addition, the suppressive effect of methylprednisolone on antibody response was alleviated in the presence of remdesivir. Thus, combinational anti-inflammatory and antiviral therapy might be an effective, safer and more versatile treatment option for COVID-19. These data support testing of the efficacy of a combination of methylprednisolone and remdesivir for the treatment of COVID-19 in randomized controlled clinical trials.

3 August 2020 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
LWLok Yin Roy Wong
Lok Yin Roy Wong
ZYZi-Wei Ye
Zi-Wei Ye
PLPak-Yin Lui
Pak-Yin Lui
XZXuyang Zheng
Xuyang Zheng
Shuofeng YuanShuofeng Yuan
Shuofeng Yuan
Dong-Yan JinDong-Yan Jin
Dong-Yan Jin
Middle East respiratory syndrome coronavirus (MERS-CoV) is a highly pathogenic human coronavirus causing severe disease and mortality. MERS-CoV infection failed to elicit robust IFN response, suggesting that the virus might have evolved strategies to evade host innate immune surveillance. In this study, we identified and characterized type I IFN antagonism of MERS-CoV open reading frame (ORF) 8b accessory protein. ORF8b was abundantly expressed in MERS-CoV–infected Huh-7 cells. When ectopically expressed, ORF8b inhibited IRF3-mediated IFN-β expression induced by Sendai virus and poly(I:C). ORF8b was found to act at a step upstream of IRF3 to impede the interaction between IRF3 kinase IKKε and chaperone protein HSP70, which is required for the activation of IKKε and IRF3. An infection study using recombinant wild-type and ORF8b-deficient MERS-CoV further confirmed the suppressive role of ORF8b in type I IFN induction and its disruption of the colocalization of HSP70 with IKKε. Ectopic expression of HSP70 relieved suppression of IFN-β expression by ORF8b in an IKKε-dependent manner. Enhancement of IFN-β induction in cells infected with ORF8b-deficient virus was erased when HSP70 was depleted. Taken together, HSP70 chaperone is important for IKKε activation, and MERS-CoV ORF8b suppresses type I IFN expression by competing with IKKε for interaction with HSP70.

31 October 2022 in Journal of Hazardous Materials
Verified
Journal Article
Closed access
XWXiaojie Wei
Xiaojie Wei
CLChengbin Liu
Chengbin Liu
HQHehe Qin
Hehe Qin
ZYZiwei Ye
Ziwei Ye
XLXinru Liu
Xinru Liu
SMShun Mao
Shun Mao

1 January 2021 in Emerging Microbes & Infections
Verified
Journal Article
Open access
DYDong Yang
Dong Yang
HIN CHUHIN CHU
HIN CHU
GLGang Lu
Gang Lu
HSHuiping Shuai
Huiping Shuai
YWYixin Wang
Yixin Wang
Jasper Fuk Woo ChanJasper Fuk Woo Chan
Jasper Fuk Woo Chan
Zika virus (ZIKV) is an emerging mosquito-borne flavivirus that poses significant threats to global public health. Macrophages and dendritic cells are both key sentinel cells in the host immune response and play critical roles in the pathogenesis of flavivirus infections. Recent studies showed that ZIKV could productively infect monocyte-derived dendritic cells (moDCs), but the role of macrophages in ZIKV infection remains incompletely understood. In this study, we first compared ZIKV infection in monocyte-derived macrophages (MDMs) and moDCs derived from the same donors. We demonstrated that while both MDMs and moDCs were susceptible to epidemic (Puerto Rico) and pre-epidemic (Uganda) strains of ZIKV, virus replication was largely restricted in MDMs but not in moDCs. ZIKV induced significant apoptosis in moDCs but not MDMs. The restricted virus replication in MDMs was not due to inefficient virus entry but was related to post-entry events in the viral replication cycle. In stark contrast with moDCs, ZIKV failed to inhibit STAT1 and STAT2 phosphorylation in MDMs. This resulted in the lack of efficient antagonism of the host type I interferon-mediated antiviral responses. Importantly, depletion of STAT2 but not STAT1 in MDMs significantly rescued the replication of ZIKV and the prototype flavivirus yellow fever virus. Overall, our findings revealed a differential interplay between macrophages and dendritic cells with ZIKV. While dendritic cells may be exploited by ZIKV to facilitate virus replication, macrophages restricted ZIKV infection.